CureVac’s Cancer Vaccine Enters Next Trial Phase
Company Announcements

CureVac’s Cancer Vaccine Enters Next Trial Phase

CureVac (CVAC) has released an update.

CureVac has initiated Part B of its Phase 1 clinical trial for the mRNA-based cancer vaccine, CVGBM, aimed at treating patients with glioblastoma. This next phase will enroll up to 20 patients to further assess the vaccine’s safety, tolerability, and immunogenicity after Part A showed no dose-limiting toxicities. CVGBM represents the company’s innovative approach to developing cancer treatments using proprietary second-generation mRNA technology.

For further insights into CVAC stock, check out TipRanks’ Stock Analysis page.

Related Articles
TipRanks Auto-Generated NewsdeskCureVac’s Latest mRNA Advances Spark Investor Interest
TipRanks Auto-Generated NewsdeskCureVac Appoints New CFO to Drive Growth
TheFlyCureVac appoints Axel Sven Malkomes as CFO
Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App